http://www.clinicaltrialsarena.com/comment/lilly-donanemab-strong-clinical-profile-leqembi/
0
0
7/19/23 at 10:25am
Organization
Clinical Trials Arena
Author
GlobalData Healthcare
40 words
0
Comments
Due to its first-to-market advantage, GlobalData expects Leqembi to dominate sales in the anti-Aβ drug class throughout 8MM in 2030 ($3.5bn)
You are the first to view
Create an account
or login to join the discussion